Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Research article

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI

Authors: Nathaniel M. Braman, Maryam Etesami, Prateek Prasanna, Christina Dubchuk, Hannah Gilmore, Pallavi Tiwari, Donna Plecha, Anant Madabhushi

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Abstract

Background

In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC).

Methods

A total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases. Feature selection was used to identify a set of top pCR-associated features from within a training set (n = 78), which were then used to train multiple machine learning classifiers to predict the likelihood of pCR for a given patient. Classifiers were then independently tested on 39 patients. Experiments were repeated separately among hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+, HER2) and triple-negative or HER2+ (TN/HER2+) tumors via threefold cross-validation to determine whether receptor status-specific analysis could improve classification performance.

Results

Among all patients, a combined intratumoral and peritumoral radiomic feature set yielded a maximum AUC of 0.78 ± 0.030 within the training set and 0.74 within the independent testing set using a diagonal linear discriminant analysis (DLDA) classifier. Receptor status-specific feature discovery and classification enabled improved prediction of pCR, yielding maximum AUCs of 0.83 ± 0.025 within the HR+, HER2 group using DLDA and 0.93 ± 0.018 within the TN/HER2+ group using a naive Bayes classifier. In HR+, HER2 breast cancers, non-pCR was characterized by elevated peritumoral heterogeneity during initial contrast enhancement. However, TN/HER2+ tumors were best characterized by a speckled enhancement pattern within the peritumoral region of nonresponders. Radiomic features were found to strongly predict pCR independent of choice of classifier, suggesting their robustness as response predictors.

Conclusions

Through a combined intratumoral and peritumoral radiomics approach, we could successfully predict pCR to NAC from pretreatment breast DCE-MRI, both with and without a priori knowledge of receptor status. Further, our findings suggest that the radiomic features most predictive of response vary across different receptor subtypes.
Appendix
Available only for authorised users
Literature
3.
go back to reference Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23 Suppl 10:x231–6.CrossRefPubMed Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23 Suppl 10:x231–6.CrossRefPubMed
4.
go back to reference Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. J Breast Cancer. 2014;17:376–85.CrossRefPubMedPubMedCentral Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. J Breast Cancer. 2014;17:376–85.CrossRefPubMedPubMedCentral
5.
go back to reference Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47:2084–90.CrossRefPubMed Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47:2084–90.CrossRefPubMed
6.
go back to reference Earl H, Provenzano E, Abraham J, Dunn J, Vallier AL, Gounaris I, et al. Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? BMC Med. 2015;13:234.CrossRefPubMedPubMedCentral Earl H, Provenzano E, Abraham J, Dunn J, Vallier AL, Gounaris I, et al. Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? BMC Med. 2015;13:234.CrossRefPubMedPubMedCentral
7.
go back to reference Marinovich ML, Sardanelli F, Ciatto S, Mamounas E, Brennan M, Macaskill P, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21:669–77.CrossRefPubMed Marinovich ML, Sardanelli F, Ciatto S, Mamounas E, Brennan M, Macaskill P, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21:669–77.CrossRefPubMed
8.
go back to reference Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology. 2003;228:63–9.CrossRefPubMed Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology. 2003;228:63–9.CrossRefPubMed
9.
go back to reference Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006;239:361–74.CrossRefPubMed Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006;239:361–74.CrossRefPubMed
10.
go back to reference Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22:1416–24.CrossRefPubMed Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22:1416–24.CrossRefPubMed
11.
12.
go back to reference Zhu Y, Li H, Guo W, Drukker K, Lan L, Giger ML, et al. Deciphering genomic underpinnings of quantitative MRI-based radiomic phenotypes of invasive breast carcinoma. Sci Rep. 2015;5:17787.CrossRefPubMedPubMedCentral Zhu Y, Li H, Guo W, Drukker K, Lan L, Giger ML, et al. Deciphering genomic underpinnings of quantitative MRI-based radiomic phenotypes of invasive breast carcinoma. Sci Rep. 2015;5:17787.CrossRefPubMedPubMedCentral
13.
go back to reference Agner SC, Rosen MA, Englander S, Tomaszewski JE, Feldman MD, Zhang P, et al. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study. Radiology. 2014;272:91–9.CrossRefPubMedPubMedCentral Agner SC, Rosen MA, Englander S, Tomaszewski JE, Feldman MD, Zhang P, et al. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study. Radiology. 2014;272:91–9.CrossRefPubMedPubMedCentral
14.
go back to reference Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, et al. Breast DCE-MRI kinetic heterogeneity tumor markers: preliminary associations with neoadjuvant chemotherapy response. Transl Oncol. 2015;8:154–62.CrossRefPubMedPubMedCentral Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, et al. Breast DCE-MRI kinetic heterogeneity tumor markers: preliminary associations with neoadjuvant chemotherapy response. Transl Oncol. 2015;8:154–62.CrossRefPubMedPubMedCentral
15.
go back to reference Guo W, Li H, Zhu Y, Lan L, Yang S, Drukker K, et al. Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data. J Med Imaging (Bellingham). 2015;2:041007.CrossRef Guo W, Li H, Zhu Y, Lan L, Yang S, Drukker K, et al. Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data. J Med Imaging (Bellingham). 2015;2:041007.CrossRef
16.
go back to reference Burnside ES, Drukker K, Li H, Bonaccio E, Zuley M, Ganott M, et al. Using computer-extracted image phenotypes from tumors on breast magnetic resonance imaging to predict breast cancer pathologic stage. Cancer. 2016;122:748–57.CrossRefPubMed Burnside ES, Drukker K, Li H, Bonaccio E, Zuley M, Ganott M, et al. Using computer-extracted image phenotypes from tumors on breast magnetic resonance imaging to predict breast cancer pathologic stage. Cancer. 2016;122:748–57.CrossRefPubMed
17.
go back to reference Li H, Lan L, Drukker K, Perou C, Giger M. TU-AB-BRA-08: radiomics in the analysis of breast cancer heterogeneity on DCE-MRI [abstract]. Med Phys. 2015;42:3588.CrossRef Li H, Lan L, Drukker K, Perou C, Giger M. TU-AB-BRA-08: radiomics in the analysis of breast cancer heterogeneity on DCE-MRI [abstract]. Med Phys. 2015;42:3588.CrossRef
18.
go back to reference Kim JH, Ko ES, Lim Y, Lee KS, Han BK, Ko EY, et al. Breast cancer heterogeneity: MR imaging texture analysis and survival outcomes. Radiology. 2017;282:665–75.CrossRefPubMed Kim JH, Ko ES, Lim Y, Lee KS, Han BK, Ko EY, et al. Breast cancer heterogeneity: MR imaging texture analysis and survival outcomes. Radiology. 2017;282:665–75.CrossRefPubMed
19.
go back to reference Wu J, Gong G, Cui Y, Li R. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy. J Magn Reson Imaging. 2016;44:1107–15.CrossRefPubMed Wu J, Gong G, Cui Y, Li R. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy. J Magn Reson Imaging. 2016;44:1107–15.CrossRefPubMed
20.
go back to reference Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer. 2016;2:16012.CrossRefPubMedPubMedCentral Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer. 2016;2:16012.CrossRefPubMedPubMedCentral
21.
go back to reference Waugh SA, Purdie CA, Jordan LB, Vinnicombe S, Lerski RA, Martin P, et al. Magnetic resonance imaging texture analysis classification of primary breast cancer. Eur Radiol. 2016;26:322–30.CrossRefPubMed Waugh SA, Purdie CA, Jordan LB, Vinnicombe S, Lerski RA, Martin P, et al. Magnetic resonance imaging texture analysis classification of primary breast cancer. Eur Radiol. 2016;26:322–30.CrossRefPubMed
22.
go back to reference Wang J, Kato F, Oyama-Manabe N, Li R, Cui Y, Tha KK, et al. Identifying triple-negative breast cancer using background parenchymal enhancement heterogeneity on dynamic contrast-enhanced MRI: a pilot radiomics study. PLoS One. 2015;10:e0143308.CrossRefPubMedPubMedCentral Wang J, Kato F, Oyama-Manabe N, Li R, Cui Y, Tha KK, et al. Identifying triple-negative breast cancer using background parenchymal enhancement heterogeneity on dynamic contrast-enhanced MRI: a pilot radiomics study. PLoS One. 2015;10:e0143308.CrossRefPubMedPubMedCentral
23.
go back to reference Sutton EJ, Dashevsky BZ, Oh JH, Veeraraghavan H, Apte AP, Thakur SB, et al. Breast cancer molecular subtype classifier that incorporates MRI features. J Magn Reson Imaging. 2016;44:122–9.CrossRefPubMed Sutton EJ, Dashevsky BZ, Oh JH, Veeraraghavan H, Apte AP, Thakur SB, et al. Breast cancer molecular subtype classifier that incorporates MRI features. J Magn Reson Imaging. 2016;44:122–9.CrossRefPubMed
24.
go back to reference Wan T, Bloch BN, Plecha D, Thompson CL, Gilmore H, Jaffe C, et al. A radio-genomics approach for identifying high risk estrogen receptor-positive breast cancers on DCE-MRI: preliminary results in predicting OncotypeDX risk scores. Sci Rep. 2016;6:21394.CrossRefPubMedPubMedCentral Wan T, Bloch BN, Plecha D, Thompson CL, Gilmore H, Jaffe C, et al. A radio-genomics approach for identifying high risk estrogen receptor-positive breast cancers on DCE-MRI: preliminary results in predicting OncotypeDX risk scores. Sci Rep. 2016;6:21394.CrossRefPubMedPubMedCentral
25.
go back to reference Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, et al. MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays. Radiology. 2016;281:382–91.CrossRefPubMedPubMedCentral Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, et al. MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays. Radiology. 2016;281:382–91.CrossRefPubMedPubMedCentral
26.
go back to reference Keller BM, Chen J, Conant EF, Kontos D. Breast density and parenchymal texture measures as potential risk factors for estrogen-receptor positive breast cancer. Proc SPIE. 2014;9035:90351D.CrossRefPubMedCentral Keller BM, Chen J, Conant EF, Kontos D. Breast density and parenchymal texture measures as potential risk factors for estrogen-receptor positive breast cancer. Proc SPIE. 2014;9035:90351D.CrossRefPubMedCentral
27.
go back to reference Wu S, Weinstein SP, DeLeo 3rd MJ, Conant EF, Chen J, Domchek SM, et al. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Res. 2015;17:67.CrossRefPubMedPubMedCentral Wu S, Weinstein SP, DeLeo 3rd MJ, Conant EF, Chen J, Domchek SM, et al. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Res. 2015;17:67.CrossRefPubMedPubMedCentral
28.
go back to reference Wu S, Berg WA, Zuley ML, Kurland BF, Jankowitz RC, Nishikawa R, et al. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. Breast Cancer Res. 2016;18:76.CrossRefPubMedPubMedCentral Wu S, Berg WA, Zuley ML, Kurland BF, Jankowitz RC, Nishikawa R, et al. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. Breast Cancer Res. 2016;18:76.CrossRefPubMedPubMedCentral
29.
go back to reference Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat. 1998;52:159–73.CrossRefPubMed Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat. 1998;52:159–73.CrossRefPubMed
31.
go back to reference Mohammed ZM, McMillan DC, Edwards J, Mallon E, Doughty JC, Orange C, et al. The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clin Pathol. 2013;13:31.CrossRefPubMedPubMedCentral Mohammed ZM, McMillan DC, Edwards J, Mallon E, Doughty JC, Orange C, et al. The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clin Pathol. 2013;13:31.CrossRefPubMedPubMedCentral
32.
go back to reference Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol. 1990;8:1457–65.CrossRefPubMed Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol. 1990;8:1457–65.CrossRefPubMed
33.
go back to reference Conklin MW, Keely PJ. Why the stroma matters in breast cancer. Cell Adhes Migr. 2012;6:249–60.CrossRef Conklin MW, Keely PJ. Why the stroma matters in breast cancer. Cell Adhes Migr. 2012;6:249–60.CrossRef
34.
go back to reference Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E. Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? J Clin Oncol. 2015;33:1298–9.CrossRefPubMed Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E. Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? J Clin Oncol. 2015;33:1298–9.CrossRefPubMed
35.
go back to reference Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7:91–101.CrossRefPubMed Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7:91–101.CrossRefPubMed
36.
go back to reference Ding C, Peng H. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol. 2005;3:185–205.CrossRefPubMed Ding C, Peng H. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol. 2005;3:185–205.CrossRefPubMed
37.
go back to reference Foley D. Considerations of sample and feature size. IEEE Trans Inf Theory. 1972;18:618–26.CrossRef Foley D. Considerations of sample and feature size. IEEE Trans Inf Theory. 1972;18:618–26.CrossRef
38.
go back to reference Brown G, Pocock A, Zhao MJ, Luján M. Conditional likelihood maximisation: a unifying framework for information theoretic feature selection. J Mach Learn Res. 2012;13:27–66. Brown G, Pocock A, Zhao MJ, Luján M. Conditional likelihood maximisation: a unifying framework for information theoretic feature selection. J Mach Learn Res. 2012;13:27–66.
39.
go back to reference Monti S, Tamayo P, Mesirov JP, Golub TR. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn. 2003;52:91–118.CrossRef Monti S, Tamayo P, Mesirov JP, Golub TR. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn. 2003;52:91–118.CrossRef
40.
42.
go back to reference Parmar C, Leijenaar RTH, Grossmann P, Rios Velazquez E, Bussink J, Rietveld D, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. Sci Rep. 2015;5:11044.CrossRefPubMedPubMedCentral Parmar C, Leijenaar RTH, Grossmann P, Rios Velazquez E, Bussink J, Rietveld D, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. Sci Rep. 2015;5:11044.CrossRefPubMedPubMedCentral
43.
go back to reference Ressom HW, Varghese RS, Zhang Z, Xuan J, Clarke R. Classification algorithms for phenotype prediction in genomics and proteomics. Front Biosci J Virtual Libr. 2008;13:691–708.CrossRef Ressom HW, Varghese RS, Zhang Z, Xuan J, Clarke R. Classification algorithms for phenotype prediction in genomics and proteomics. Front Biosci J Virtual Libr. 2008;13:691–708.CrossRef
44.
go back to reference Ku YJ, Kim HH, Cha JH, Shin HJ, Baek SH, Lee HJ, et al. Correlation between MRI and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. AJR Am J Roentgenol. 2016;207:1146–51.CrossRefPubMed Ku YJ, Kim HH, Cha JH, Shin HJ, Baek SH, Lee HJ, et al. Correlation between MRI and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. AJR Am J Roentgenol. 2016;207:1146–51.CrossRefPubMed
45.
go back to reference Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13.CrossRefPubMedPubMedCentral Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13.CrossRefPubMedPubMedCentral
46.
go back to reference Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342–54.CrossRefPubMed Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342–54.CrossRefPubMed
47.
go back to reference Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015;3:607–13.PubMedPubMedCentral Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015;3:607–13.PubMedPubMedCentral
48.
go back to reference Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, et al. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res. 2009;11:R23.CrossRefPubMedPubMedCentral Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, et al. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res. 2009;11:R23.CrossRefPubMedPubMedCentral
49.
go back to reference Munzone E, Bagnardi V, Rotmensz N, Sporchia A, Mazza M, Pruneri G, et al. Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. Breast Cancer Res Treat. 2014;146:573–82.CrossRefPubMed Munzone E, Bagnardi V, Rotmensz N, Sporchia A, Mazza M, Pruneri G, et al. Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. Breast Cancer Res Treat. 2014;146:573–82.CrossRefPubMed
50.
go back to reference Blaschke E, Abe H. MRI phenotype of breast cancer: kinetic assessment for molecular subtypes. J Magn Reson Imaging. 2015;42:920–4.CrossRefPubMed Blaschke E, Abe H. MRI phenotype of breast cancer: kinetic assessment for molecular subtypes. J Magn Reson Imaging. 2015;42:920–4.CrossRefPubMed
51.
go back to reference Kawashima H, Inokuchi M, Furukawa H, Ikeda H, Kitamura S. Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects. Springerplus. 2014;3:240.CrossRefPubMedPubMedCentral Kawashima H, Inokuchi M, Furukawa H, Ikeda H, Kitamura S. Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects. Springerplus. 2014;3:240.CrossRefPubMedPubMedCentral
52.
go back to reference Yoshikawa R, Teramoto A, Matsubara T, Fujita H. Automated detection of architectural distortion using improved adaptive Gabor filter. In: Fujita H, Hara T, Muramatsu C, editors. Breast Imaging. IWDM. Lecture Notes in Computer Science. 2014;8539:606–11. Yoshikawa R, Teramoto A, Matsubara T, Fujita H. Automated detection of architectural distortion using improved adaptive Gabor filter. In: Fujita H, Hara T, Muramatsu C, editors. Breast Imaging. IWDM. Lecture Notes in Computer Science. 2014;8539:606–11.
53.
go back to reference Rangayyan RM, Banik S, Chakraborty J, Mukhopadhyay S, Desautels JEL. Measures of divergence of oriented patterns for the detection of architectural distortion in prior mammograms. Int J Comput Assist Radiol Surg. 2012;8:527–45.CrossRefPubMed Rangayyan RM, Banik S, Chakraborty J, Mukhopadhyay S, Desautels JEL. Measures of divergence of oriented patterns for the detection of architectural distortion in prior mammograms. Int J Comput Assist Radiol Surg. 2012;8:527–45.CrossRefPubMed
54.
go back to reference Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13:202.CrossRefPubMedPubMedCentral Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13:202.CrossRefPubMedPubMedCentral
55.
go back to reference Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, et al. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015;154:239–49.CrossRefPubMed Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, et al. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015;154:239–49.CrossRefPubMed
56.
go back to reference Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793–805.CrossRefPubMed Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793–805.CrossRefPubMed
57.
go back to reference Orooji M, Rakshit S, Beig N, Madabhushi A, Velcheti V. Computerized textural analysis of lung CT to enable quantification of tumor infiltrating lymphocytes in NSCLC [abstract]. J Clin Oncol. 2016;34:11584. Orooji M, Rakshit S, Beig N, Madabhushi A, Velcheti V. Computerized textural analysis of lung CT to enable quantification of tumor infiltrating lymphocytes in NSCLC [abstract]. J Clin Oncol. 2016;34:11584.
58.
go back to reference Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24 Suppl 2:S26–35.CrossRefPubMed Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24 Suppl 2:S26–35.CrossRefPubMed
59.
go back to reference Prasanna P, Tiwari P, Madabhushi A. Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe): distinguishing tumor confounders and molecular subtypes on MRI. Med Image Comput Comput Assist Interv. 2014;17:73–80.PubMed Prasanna P, Tiwari P, Madabhushi A. Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe): distinguishing tumor confounders and molecular subtypes on MRI. Med Image Comput Comput Assist Interv. 2014;17:73–80.PubMed
60.
go back to reference Prasanna P, Tiwari P, Madabhushi A. Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe): a new radiomics descriptor. Sci Rep. 2016;6:37241.CrossRefPubMedPubMedCentral Prasanna P, Tiwari P, Madabhushi A. Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe): a new radiomics descriptor. Sci Rep. 2016;6:37241.CrossRefPubMedPubMedCentral
Metadata
Title
Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
Authors
Nathaniel M. Braman
Maryam Etesami
Prateek Prasanna
Christina Dubchuk
Hannah Gilmore
Pallavi Tiwari
Donna Plecha
Anant Madabhushi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0846-1

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine